EG LEASING (00379) announced that after fair negotiations between the contracting parties, on September 9, 2025, Shanghai Lizhu Biotechnology, an indirect wholly-owned subsidiary of the company, as the seller, entered into a termination agreement with Genocell. Both parties agreed to terminate the old agreement from the date of the termination agreement. Within 7 days after Solarbio (the buyer under the new agreement and five agreements) receives the new consideration, the seller will refund the initial deposit of RMB 1.2592 million (equivalent to approximately HK$1.372 million) that Genocell preliminarily paid to the seller under the old agreement.

On September 9, 2025, the seller agreed to sell and Solarbio agreed to purchase the 103 properties for a new consideration of RMB 6.3682 million (equivalent to approximately HK$6.941 million). Solarbio is also the buyer under the five agreements. For further details regarding the five agreements, please refer to the company's announcement dated August 22, 2025.

Given that both the new agreement and the five agreements are entered into with Solarbio and will be completed within 12 months, under Rule 14.22 of the Listing Rules, the sale of the 103 properties and those properties are aggregated as if they were a single transaction.

The new consideration of RMB 6.3682 million (equivalent to approximately HK$6.941 million) under the new agreement is higher than the consideration under the old agreement. Furthermore, the group also received the full new consideration after entering into the new agreement, and no significant costs were incurred for terminating the old agreement.

The board of directors believes that the terms and conditions of the termination agreement and the new agreement were entered into on normal commercial terms, are fair and reasonable, and are in the overall interests of the company and its shareholders.